Chief Technical Officer Joseph Shulman Sells Shares of Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity, has reported an insider sell according to a recent SEC filing. Chief Technical Officer Joseph Shulman sold 2,954 shares of the company on February 14, 2024. The transaction was disclosed in an SEC Filing.
Over the past year, the insider has sold a total of 118,147 shares and has not made any purchases of the stock. The recent sell by the insider contributes to a trend observed over the past year, where there have been no insider buys and 23 insider sells for Rhythm Pharmaceuticals Inc.
On the date of the insider's recent sell, shares of Rhythm Pharmaceuticals Inc were trading at $50 each, valuing the company at a market cap of $2.982 billion.
The insider transaction history indicates a pattern of sales by insiders, which could be of interest to shareholders and potential investors as they evaluate the company's stock performance and insider sentiment.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
